CJ Wang – CEO, Frontier Biotech, China
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Address: Room 301,E unit, 3rd Building,Helicon Garden (Hongjialiyuan), Haidian District,Beijing 100088,China
Tel: (86-10)82050626
Formed in May 1988, the purpose of CNMA is to promote and raise the level of research, production and sales management of the Chinese OTC industry in compliance with social ethics and the relevant laws, regulations and policies.
CNMA represents the members’interests and submits policy advices to the concerned government departments on drugs’ classification, OTC research, production and sale.
CNMA also provides the members with consulting, training and information services to promote OTC technology, enhance OTC quality and ensure the consumers’ safety in using OTC products.
Another key role is to raise the knowledge and awareness about self-medication and OTC products. CNMA also organizes different activities to strengthen cooperation and contacts with international organizations, OTC associations and enterprises.
Industry Regulation and Coordination, Education
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the…
Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the…
John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific…
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.…
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization),…
Geoff Kau, Co-GM and CSO of Ping An Smart City, introduces the breathtaking breadth of the Ping An healthcare ecosystem, and the interesting projects his subsidiary, Ping An Smart City,…
Charles Bark, CEO and founder of HiNounou, shares the touching personal story of what inspired him to establish HiNounou as a complete remote healthcare solution package for elderly people; how…
China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
Wang Wei of Winhealth Pharma, one of China’s leading contract development and commercialisation organisations, outlines the rationale behind the company’s formation, how its business model is changing to keep up…
See our Cookie Privacy Policy Here